Sujal Deshmukh obtained a PhD in Pharmacology and Toxicology from the University of Texas Medical Brach – Galveston. Following his PhD, he joined Merck Research Laboratories DMPK department supporting projects in the discovery phase. He subsequently joined Novartis where he is responsible for overseeing the Global In Vitro ADME group focused on evaluating and characterizing the in vitro clearance, permeability, drug-drug interaction and distribution properties of new molecules.